Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. Gilead and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.One of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.
The report details the trend, potential and market size of Heart Failure Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Heart Failure Drugsmarket, defines the market attractiveness level of Heart Failure Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Heart Failure Drugs industry, describes the types of Heart Failure Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Heart Failure Drugs market and the development prospects and opportunities of Heart Failure Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Heart Failure Drugs market in Chapter 13.
By Player:
Bayer
Gilead
AstraZeneca
Novartis
GlaxoSmithKline
Teva Pharmaceutical industries
Pfizer
Amgen
By Type:
Beta Blockers
ARBs
ACE Inhibitors
By End-User:
Hospital
Pharmacy
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Heart Failure Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Heart Failure Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Heart Failure Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Heart Failure Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Heart Failure Drugs Market Analysis and Outlook to 2022
-
7.1 Global Heart Failure Drugs Consumption (2017-2022)
-
7.2 United States Heart Failure Drugs Consumption (2017-2022)
-
7.3 Europe Heart Failure Drugs Consumption (2017-2022)
-
7.4 China Heart Failure Drugs Consumption (2017-2022)
-
7.5 Japan Heart Failure Drugs Consumption (2017-2022)
-
7.6 India Heart Failure Drugs Consumption (2017-2022)
-
7.7 South Korea Heart Failure Drugs Consumption (2017-2022)
8 Region and Country-wise Heart Failure Drugs Market Analysis and Outlook to 2028
-
8.1 Global Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.2 United States Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.3 Europe Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.4 China Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.5 Japan Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.6 India Heart Failure Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea Heart Failure Drugs Consumption Forecast (2022-2028)
9 Global Heart Failure Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Heart Failure Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Beta Blockers Consumption and Growth Rate (2017-2022)
-
9.1.2 Global ARBs Consumption and Growth Rate (2017-2022)
-
9.1.3 Global ACE Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Heart Failure Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Pharmacy Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Heart Failure Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global Heart Failure Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Beta Blockers Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global ARBs Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global ACE Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Heart Failure Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Heart Failure Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global Heart Failure Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Heart Failure Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Heart Failure Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Heart Failure Drugs Market Competitive Analysis
-
14.1 Bayer
-
14.1.1 Bayer Company Details
-
14.1.2 Bayer Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Bayer Heart Failure Drugs Product and Service
-
14.2 Gilead
-
14.2.1 Gilead Company Details
-
14.2.2 Gilead Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Gilead Heart Failure Drugs Product and Service
-
14.3 AstraZeneca
-
14.3.1 AstraZeneca Company Details
-
14.3.2 AstraZeneca Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AstraZeneca Heart Failure Drugs Product and Service
-
14.4 Novartis
-
14.4.1 Novartis Company Details
-
14.4.2 Novartis Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Novartis Heart Failure Drugs Product and Service
-
14.5 GlaxoSmithKline
-
14.5.1 GlaxoSmithKline Company Details
-
14.5.2 GlaxoSmithKline Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 GlaxoSmithKline Heart Failure Drugs Product and Service
-
14.6 Teva Pharmaceutical industries
-
14.6.1 Teva Pharmaceutical industries Company Details
-
14.6.2 Teva Pharmaceutical industries Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Teva Pharmaceutical industries Heart Failure Drugs Product and Service
-
14.7 Pfizer
-
14.7.1 Pfizer Company Details
-
14.7.2 Pfizer Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Pfizer Heart Failure Drugs Product and Service
-
14.8 Amgen
-
14.8.1 Amgen Company Details
-
14.8.2 Amgen Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Amgen Heart Failure Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Heart Failure Drugs
-
Figure Heart Failure Drugs Picture
-
Table Global Heart Failure Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Heart Failure Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Heart Failure Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Heart Failure Drugs Consumption by Country (2017-2022)
-
Figure United States Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Figure China Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Heart Failure Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Heart Failure Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Heart Failure Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Beta Blockers Consumption and Growth Rate (2017-2022)
-
Figure Global ARBs Consumption and Growth Rate (2017-2022)
-
Figure Global ACE Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Pharmacy Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Beta Blockers Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global ARBs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global ACE Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Heart Failure Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Heart Failure Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Heart Failure Drugs Product and Service
-
Table Gilead (Foundation Year, Company Profile and etc.)
-
Table Gilead Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Heart Failure Drugs Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Heart Failure Drugs Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Heart Failure Drugs Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Heart Failure Drugs Product and Service
-
Table Teva Pharmaceutical industries (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical industries Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical industries Heart Failure Drugs Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Heart Failure Drugs Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Heart Failure Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Heart Failure Drugs Product and Service
-
